Oncology Clinical Trials in San Francisco, CA

As of September 2026, 257 paid clinical trials are recruiting for Oncology in San Francisco, California. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 1, 2026.

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

258 clinical trials for Oncology

·Clear filters·

Email me when a new oncology trial opens in San Francisco, CA.

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

for Breast Cancer

Sites in San Francisco, Los Angeles +22 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT05768139·Phase 1, Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

for Triple Negative Breast Cancer

Sites in San Francisco, Santa Monica +24 more locations

Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT05377996·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

for Breast Cancer

Drug: Palazestrant

Sites in San Francisco, Vallejo +31 more locations

Sponsor: Olema Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT07085767·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

for Follicular Lymphoma

Drug: Golcadomide

Sites in San Francisco, Duarte +29 more locations

Sponsor: Celgene

Sex: All·Age: 18+

Code: NCT06911502·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

Sites in San Francisco, Los Angeles +36 more locations

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06297226·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Galleri® in the Medicare Population.

for Cancer

Sites in San Francisco, Vallejo +59 more locations

Sponsor: GRAIL, Inc.

Sex: All·Age: 50+·Accepts healthy volunteers

Code: NCT05673018·Recruiting·Listed Jan 2023

Apply to this trial

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

for Breast Cancer

Sites in San Francisco, Redding +111 more locations

Sponsor: Agendia

Sex: All·Age: 18+

Code: NCT03053193·Recruiting·Listed Feb 2017

Apply to this trial

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

for Cancer, Metastatic

Sites in San Francisco, Stanford +65 more locations

Sponsor: Massive Bio, Inc.

Sex: All·Age: All ages

Code: NCT03452774·Recruiting·Listed Mar 2018

Apply to this trial

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

for Pancreatic Cancer

Drug: daraxonrasib

Sites in San Francisco +12 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT07491445·Phase 3·Recruiting·Listed Mar 2026

Apply to this trial

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

for Lymphoma, Non-Hodgkin's

Drug: LY4584180

Sites in San Francisco, Los Angeles +19 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07226843·Phase 1·Recruiting·Listed Nov 2025

Apply to this trial

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

for Bladder Cancer

Sites in San Francisco, Los Angeles +13 more locations

Sponsor: EvolveImmune United, Inc

Sex: All·Age: 18+

Code: NCT07217171·Phase 1·Recruiting·Listed Oct 2025

Apply to this trial

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

for Breast Cancer

Drug: Giredestrant

Sites in San Francisco, Duarte +24 more locations

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT07100106·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

for Locally Advanced or Metastatic Solid Tumors

Sites in San Francisco, Los Angeles +8 more locations

Sponsor: ArriVent BioPharma, Inc.

Sex: All·Age: 18+

Code: NCT07066657·Phase 1·Recruiting·Listed Jul 2025

Apply to this trial

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

for Advanced Solid Tumor

Sites in San Francisco +17 more locations

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT07070232·Phase 1, Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

for Ovarian Cancer

Sites in San Francisco, Palo Alto +15 more locations

Sponsor: Xencor, Inc.

Sex: All·Age: 15+

Code: NCT06276491·Phase 1·Recruiting·Listed Feb 2024

Apply to this trial

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

for Metastatic Castration-Resistant Prostate Cancer

Sites in San Francisco, Los Angeles +21 more locations

Sponsor: Kyntra Bio

Sex: Male·Age: 18+

Code: NCT06842498·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

for Solid Tumor

Sites in San Francisco +10 more locations

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT06952010·Phase 1·Recruiting·Listed Apr 2025

Apply to this trial

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

for Multiple Myeloma

Sites in San Francisco +16 more locations

Sponsor: K36 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05651932·Phase 1·Recruiting·Listed Dec 2022

Apply to this trial

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

for Glioblastoma

Sites in San Francisco, Los Angeles +14 more locations

Sponsor: CarThera

Sex: All·Age: 18+

Code: NCT05902169·Phase 3·Recruiting·Listed Jun 2023

Apply to this trial

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

for Melanoma Stage IV

Sites in San Francisco, Bakersfield +9 more locations

Sponsor: Georgiamune Inc

Sex: All·Age: 18+

Code: NCT06425926·Phase 1, Phase 2·Recruiting·Listed May 2024

Apply to this trial

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

for Solid Tumor

Sites in San Francisco, Los Angeles +18 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18+

Code: NCT04939610·Phase 1, Phase 2·Recruiting·Listed Jun 2021

Apply to this trial

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

for Metastatic Melanoma

Drug: Lifileucel

Sites in San Francisco, Los Angeles +16 more locations

Sponsor: Iovance Biotherapeutics, Inc.

Sex: All·Age: 18 - 70

Code: NCT05727904·Phase 3·Recruiting·Listed Feb 2023

Apply to this trial

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

for SST2-positive Neuroendocrine Neoplasms

Sites in San Francisco, Duarte +21 more locations

Sponsor: Crinetics Pharmaceuticals Inc.

Sex: All·Age: 18+

Code: NCT07129252·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

Sites in San Francisco +13 more locations

Sponsor: Debiopharm International SA

Sex: All·Age: 12+

Code: NCT04855656·Phase 1·Recruiting·Listed Apr 2021

Apply to this trial

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

for Advanced Solid Tumors

Sites in San Francisco, Newport Beach +8 more locations

Sponsor: Ensem Therapeutics

Sex: All·Age: 18+

Code: NCT06993844·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

A Study of ZL-1310 in Participants With Selected Solid Tumors

for Solid Tumors

Drug: ZL-1310

Sites in San Francisco +11 more locations

Sponsor: Zai Lab (Shanghai) Co., Ltd.

Sex: All·Age: 18+

Code: NCT06885281·Phase 1, Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

for Myelofibrosis

Sites in San Francisco, Los Angeles +22 more locations

Sponsor: Disc Medicine, Inc

Sex: All·Age: 18+

Code: NCT05320198·Phase 1, Phase 2·Recruiting·Listed Apr 2022

Apply to this trial

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

for Metastatic Castration-resistant Prostate Cancer

Sites in San Francisco +12 more locations

Sponsor: K36 Therapeutics, Inc.

Sex: Male·Age: 18+

Code: NCT07103018·Phase 1·Recruiting·Listed Aug 2025

Apply to this trial

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

for Solid Tumor, Adult

Sites in San Francisco, Los Angeles +17 more locations

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06625775·Phase 1·Recruiting·Listed Oct 2024

Apply to this trial

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

for Advanced Solid Tumors

Sites in San Francisco, Los Angeles +12 more locations

Sponsor: ModernaTX, Inc.

Sex: All·Age: 12+

Code: NCT05533697·Phase 1, Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

for Urothelial Carcinoma

Sites in San Francisco, Orange +7 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT05562830·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

for Non-Small Cell Lung Cancer

Sites in San Francisco, Sacramento +14 more locations

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06917079·Phase 1·Recruiting·Listed Apr 2025

Apply to this trial

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

for Metastatic Castration-Resistant Prostate Cancer

Sites in San Francisco, Los Angeles +12 more locations

Sponsor: Zenith Epigenetics

Sex: Male·Age: 18+

Code: NCT04986423·Phase 2·Recruiting·Listed Aug 2021

Apply to this trial

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

for Ewing Sarcoma

Sites in San Francisco, Santa Monica +16 more locations

Sponsor: Inhibrx Biosciences, Inc

Sex: All·Age: 12 - 85

Code: NCT03715933·Phase 1·Recruiting·Listed Oct 2018

Apply to this trial

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

Sites in San Francisco, Santa Monica +20 more locations

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06343402·Phase 1·Recruiting·Listed Apr 2024

Apply to this trial

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

for Melanoma

Drug: Cemiplimab

Sites in San Francisco, Los Angeles +9 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06413680·Phase 1, Phase 2·Recruiting·Listed May 2024

Apply to this trial

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

for Oncology

Sites in San Francisco +12 more locations

Sponsor: Nested Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06326411·Phase 1·Recruiting·Listed Mar 2024

Apply to this trial

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

for Non Small Cell Lung Cancer

Sites in San Francisco, Los Angeles +13 more locations

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06810544·Phase 1, Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

for Advanced Solid Tumors With KRAS G12C Mutations

Drug: FMC-376

Sites in San Francisco, La Jolla +10 more locations

Sponsor: Frontier Medicines Corporation

Sex: All·Age: 18+

Code: NCT06244771·Phase 1, Phase 2·Recruiting·Listed Feb 2024

Apply to this trial

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

for Endometrial Cancer

Sites in San Francisco, La Jolla +16 more locations

Sponsor: Faeth Therapeutics

Sex: Female·Age: 18+

Code: NCT06463028·Phase 2·Recruiting·Listed Jun 2024

Apply to this trial

Conditions in Oncology (San Francisco, CA)

Solid tumor· 47 Prostate cancer· 32 Breast cancer· 30 Non-small cell lung cancer (NSCLC)· 26 Cancer (any)· 18 Metastatic prostate cancer· 16 Glioblastoma· 16 Metastatic breast cancer· 14 Colorectal cancer· 14 Bladder cancer· 12 Acute myeloid leukemia (AML)· 12 Melanoma· 12 Pancreatic cancer· 11 Ovarian cancer· 11 Multiple myeloma· 10 Non-Hodgkin lymphoma· 10 Endometrial cancer· 8 Liver cancer· 7 Glioma· 7 Hematologic malignancy· 7 Neuroblastoma· 7 Pediatric cancer· 7 Kidney cancer· 6 Brain cancer· 6 Leukemia (other)· 6 Triple-negative breast cancer· 5 Myelodysplastic syndromes (MDS)· 5 Follicular lymphoma· 5 HER2-negative breast cancer· 4 Fallopian tube cancer· 4 Diffuse large B-cell lymphoma (DLBCL)· 4 Mantle cell lymphoma· 4 Head and neck cancer· 4 Neuroendocrine tumors· 4 Lung cancer· 3 Gastric cancer· 3 Biliary tract cancer· 3 Cervical cancer· 3 Gynecologic cancer· 3 Small lymphocytic lymphoma· 3 Thyroid cancer· 3 HER2-positive breast cancer· 2 Colon cancer· 2 Uterine cancer· 2 Chronic lymphocytic leukemia (CLL)· 2 Acute lymphoblastic leukemia· 2 Myelofibrosis· 2 Myeloproliferative neoplasm· 2 Hodgkin lymphoma· 2 Osteosarcoma· 2 Ewing sarcoma· 2 Rhabdomyosarcoma· 2 Small cell lung cancer· 1 Metastatic colorectal cancer· 1 Gastroesophageal junction cancer· 1 Gastrointestinal cancer· 1 Brain metastases· 1 Marginal zone lymphoma· 1 Burkitt lymphoma· 1 Sarcoma· 1 Soft tissue sarcoma· 1 Mesothelioma· 1